<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the effects of AZD1152, an Aurora B kinase inhibitor, on Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) in human tissues and cell cultures and in a murine <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Aurora kinase A and B levels were assessed by RT-PCR and immunohistochemistry </plain></SENT>
<SENT sid="2" pm="."><plain>They were aberrantly expressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> cell lines, and in lymph nodes from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Next, activation of the Aurora B promoter was detected by reporter gene assays </plain></SENT>
<SENT sid="4" pm="."><plain>The promoter activity of Aurora B kinase was high in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines and the Aurora B promoter contained a positive regulatory region between -74 and -104 from the transcription initiation site </plain></SENT>
<SENT sid="5" pm="."><plain>AZD1152-hQPA had antiproliferative effects in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> cell lines studied; inhibited the phosphorylation of <z:chebi fb="0" ids="15358">histone</z:chebi> H3 and <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> proteins, and resulted in cells with &gt; 4N DNA content </plain></SENT>
<SENT sid="6" pm="."><plain>AZD1152-hQPA induced caspase-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of some cell lines, demonstrated by loss of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential, activation of caspase-9, followed by activation of caspase-3 </plain></SENT>
<SENT sid="7" pm="."><plain>This effect was accompanied by the inhibition of survivin expression </plain></SENT>
<SENT sid="8" pm="."><plain>In vivo efficacy was determined in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp>/Î³c(null) mice implanted with the Ramos human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line </plain></SENT>
<SENT sid="9" pm="."><plain>AZD1152 had anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> effects in this murine <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>There preclinical data suggest that the inhibition of Aurora B kinase is a potentially useful therapeutic strategy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
</text></document>